Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) EBITDA Margin (2018 - 2025)

Lipocine (LPCN) has disclosed EBITDA Margin for 9 consecutive years, with 2776.34% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin changed N/A year-over-year to 2776.34%, compared with a TTM value of 126.79% through Sep 2025, down 7216.0%, and an annual FY2024 reading of 0.09%, up 57272.0% over the prior year.
  • EBITDA Margin was 2776.34% for Q3 2025 at Lipocine, down from 355.22% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 11817.87% in Q2 2021 and bottomed at 6995.38% in Q1 2023.
  • Average EBITDA Margin over 5 years is 306.56%, with a median of 284.11% recorded in 2025.
  • The sharpest move saw EBITDA Margin crashed -1234773bps in 2022, then surged 704127bps in 2024.
  • Year by year, EBITDA Margin stood at 78.39% in 2021, then plummeted by -776bps to 529.85% in 2022, then soared by 231bps to 693.04% in 2023, then tumbled by -93bps to 51.02% in 2024, then tumbled by -5541bps to 2776.34% in 2025.
  • Business Quant data shows EBITDA Margin for LPCN at 2776.34% in Q3 2025, 355.22% in Q2 2025, and 1990.64% in Q1 2025.